Inpharmus

Inpharmus İnovatif çözümleri sağlıkla buluşturuyoruz!

In clinical oncology, the key barrier is not the lack of data, but its interpretation.Healthcare systems are increasingl...
08/06/2026

In clinical oncology, the key barrier is not the lack of data, but its interpretation.

Healthcare systems are increasingly “data rich, information poor.” High statistical reliability can mask clinicalvariability. The same evidence can lead to different policy decisions. And genomic data often remains a grayzone in practice.

The focus must shift from generating more data to standardizing how we interpret it. Real-world evidenceand multidisciplinary alignment are critical to turning data into meaningful outcomes.

Strong clinical evidence is fundamental. It defines what is possible under controlled conditions. Yet, what happens in p...
05/06/2026

Strong clinical evidence is fundamental. It defines what is possible under controlled conditions. Yet, what happens in practice isshaped by a different set of realities.

In clinical settings, adoption is rarely driven by effectiveness alone. It is influenced by how well an approach fits into existing workflows, howeasily teams can coordinate around it, and how seamlessly it integrates into patient pathways.

Operational alignment, timing, resource availability, and day-to-day practicality often determine whether evidence translates into impact.

This is why some approaches, despite compelling efficacy data, struggle to find their place in routine care. Others, with balanced performanceand high feasibility, are more readily adopted and sustained.

The real question may not be effectiveness or feasibility, but how well these two dimensions align.

Clinical research generates evidence, but it also shows where evidence is still limited.These gaps are part of the proce...
20/05/2026

Clinical research generates evidence, but it also shows where evidence is still limited.

These gaps are part of the process.

They guide new studies, support better decisions, and contribute to improving patient care.

Value in healthcare is not only about extending life, but improving the life extended.In health economics, value is comm...
11/05/2026

Value in healthcare is not only about extending life, but improving the life extended.

In health economics, value is commonly operationalized through the Quality-Adjusted Life Year (QALY), a metric thatintegrates survival duration with health-related quality-of-life weights into a single outcome. This enables decision-makers to assess therapies not only by how long patients live, but by how well they live.

The National Institute for Health and Care Excellence uses cost per QALY gained as a central criterion in its technologyappraisals, while the Institute for Clinical and Economic Review incorporates QALY-based analyses within its valueassessment framework, including long-term and budget impact considerations.

Within this model, Patient-Reported Outcomes are critical inputs. The U.S. Food and Drug Administration defines PROsas direct reports from patients about how they feel or function without external interpretation. Because these measuresinform health-state utility values, they can influence cost-effectiveness results and, ultimately, reimbursementconclusions.

For pharmaceutical strategy, this is decisive. Survival gains matter. But validated improvements in quality of life canshape HTA outcomes, pricing discussions, and long-term access.

In value-based systems, survival is quantified in years. Reimbursement decisions are increasingly shaped by the qualityof those years.

Brain Tumor Awareness Month highlights a critical reality:Outcomes in neuro-oncology are shaped not only by scientific p...
04/05/2026

Brain Tumor Awareness Month highlights a critical reality:

Outcomes in neuro-oncology are shaped not only by scientific progress, but by how timely andeffectively care is delivered.

Molecular classification has become integral to diagnosis, increasing both precision and complexity.At the same time, evidence shows that delays in treatment pathways are associated with worsesurvival outcomes.

The challenge is no longer only what is scientifically possible, but what can be consistently deliveredin clinical practice.

Scientific progress must be matched with operational precision.

28/04/2026

As part of World Primary Immunodeficiencies Week and World Immunology Day, we came together in Ankara with Prof. Dr. Feyzi İlhan Tezcan to support awareness.

Early diagnosis and effective treatment can change lives in primary immunodeficiencies. We remain committed to raising awareness together.

Testicular cancer is the most common solid tumor in men aged 15–44. Most cases are germ cell tumors,accounting for 90–95...
24/04/2026

Testicular cancer is the most common solid tumor in men aged 15–44. Most cases are germ cell tumors,accounting for 90–95% of all testicular cancers.The average age at diagnosis is 33 years.

Established risk factors include a history of undescended te**is (cryptorchidism), family history, genetic susceptibility, andearly-life environmental exposures, all of which contribute to increased susceptibility to germ cell tumors.

Early signs of testicular cancer typically include a lump, swelling, or change in size of a testicle, which may be painless oraccompanied by discomfort or a dull ache in the lower abdomen or groin.

Prognosis is generally excellent. Localized disease has a five-year survival above 99%, and even metastatic germ celltumors achieve high cure rates with proper management.

Promoting awareness and encouraging open discussions may help support early detection and timely care.

‘’The information shared on this page is not intended to replace the advice of a doctor or pharmacist. For more detailed information, please consult your doctor or pharmacist.’’

Primary Immunodeficiencies are often described as “rare.”Yet in clinical practice, the real challenge is not rarity alon...
22/04/2026

Primary Immunodeficiencies are often described as “rare.”

Yet in clinical practice, the real challenge is not rarity alone, but recognition.

Delayed diagnoses, heterogeneous presentations, and fragmented care pathways continue to shape patient outcomes.

Initiatives like World PI Week remind us that awareness is not the endpoint.

It is the starting point for earlier suspicion, more accurate diagnosis, and equitable access to care.

Because in Primary Immunodeficiencies, what remains unseen often defines the patient journey.

Address

Esentepe, Büyükdere Caddesi Kanyon Ofis Bloğu No: 185 Kat: 14, 34394 Levent/Şişli/Şişli/Istanbul
Istanbul
34000

Website

Alerts

Be the first to know and let us send you an email when Inpharmus posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share

Category